[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HRP20000181B1 - 2-methyl-thieno-benzodiazepine formulation - Google Patents

2-methyl-thieno-benzodiazepine formulation

Info

Publication number
HRP20000181B1
HRP20000181B1 HR20000181A HRP20000181A HRP20000181B1 HR P20000181 B1 HRP20000181 B1 HR P20000181B1 HR 20000181 A HR20000181 A HR 20000181A HR P20000181 A HRP20000181 A HR P20000181A HR P20000181 B1 HRP20000181 B1 HR P20000181B1
Authority
HR
Croatia
Prior art keywords
thieno
methyl
formulation
benzodiazepine formulation
benzodiazepine
Prior art date
Application number
HR20000181A
Other languages
English (en)
Croatian (hr)
Inventor
Allen Douglas James
Douglas Dekemper Kurt
Harry Ferguson Thomas
James Garvin Stuart
Cameron Murray Linda
Dale Brooks Norman
Arthur Bunnell Charles
Arnold Hendriksen Barry
Singh Mascarenhas Snehlata
Louise Shinkle Sharon
Vicente Sanchez-Felix Manuel
Edward Tupper David
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20000181A2 publication Critical patent/HRP20000181A2/hr
Publication of HRP20000181B1 publication Critical patent/HRP20000181B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
HR20000181A 1997-09-30 1998-09-30 2-methyl-thieno-benzodiazepine formulation HRP20000181B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6049397P 1997-09-30 1997-09-30
PCT/US1998/020426 WO1999016313A1 (en) 1997-09-30 1998-09-30 2-methyl-thieno-benzodiazepine formulation

Publications (2)

Publication Number Publication Date
HRP20000181A2 HRP20000181A2 (en) 2000-12-31
HRP20000181B1 true HRP20000181B1 (en) 2006-07-31

Family

ID=22029843

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20000181A HRP20000181B1 (en) 1997-09-30 1998-09-30 2-methyl-thieno-benzodiazepine formulation

Country Status (20)

Country Link
US (1) US6169084B1 (xx)
EP (1) EP1018880A4 (xx)
JP (2) JP4503826B2 (xx)
KR (1) KR100537713B1 (xx)
CN (1) CN1239158C (xx)
AU (1) AU752552C (xx)
BR (1) BR9813228A (xx)
CA (1) CA2304568C (xx)
CZ (1) CZ300725B6 (xx)
EA (1) EA002825B1 (xx)
HR (1) HRP20000181B1 (xx)
HU (1) HUP0004534A3 (xx)
ID (1) ID25533A (xx)
IL (2) IL135295A0 (xx)
NO (1) NO20001631L (xx)
NZ (1) NZ503641A (xx)
PL (1) PL339864A1 (xx)
TR (1) TR200000812T2 (xx)
UA (1) UA73715C2 (xx)
WO (1) WO1999016313A1 (xx)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617321B2 (en) * 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
HK1041199B (en) * 1998-09-30 2005-03-18 Eli Lilly & Company 2-Methyl-thiophenone-benzodiazine formula
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US20040067936A1 (en) * 2000-08-31 2004-04-08 Reguri Buchi Reddy Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
US6988887B2 (en) * 2002-02-18 2006-01-24 3M Innovative Properties Company Orthodontic separators
EP1575962A1 (en) * 2002-12-24 2005-09-21 Teva Pharmaceutical Industries Limited Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
HU226410B1 (en) * 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
ATE504588T1 (de) 2004-01-27 2011-04-15 Synthon Bv Stabile salze von olanzapin
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
ES2253091B1 (es) * 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
US20090155331A1 (en) * 2005-11-16 2009-06-18 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
WO2006055603A2 (en) * 2004-11-16 2006-05-26 Elan Pharma International Ltd. Injectable nanoparticulate olanzapine formulations
CA2593471A1 (en) * 2004-12-10 2006-07-06 University Of Connecticut Shape memory polymer orthodontic appliances, and methods of making and using the same
JP4940152B2 (ja) * 2005-01-05 2012-05-30 イーライ リリー アンド カンパニー パモ酸オランザピン二水和物
CZ2006697A3 (cs) * 2006-11-07 2008-05-21 Zentiva, A. S. Kompozice depotních olanzapinových injekcních systému
US9161943B2 (en) 2007-12-31 2015-10-20 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
US8449903B2 (en) * 2009-06-08 2013-05-28 Boston Scientific Scimed, Inc. Crosslinked bioabsorbable medical devices
AU2010264670A1 (en) 2009-06-24 2012-01-19 Merck Sharp & Dohme B.V. Injectable formulations containing asenapine and method of treatment using same
WO2011091142A2 (en) 2010-01-20 2011-07-28 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous forms of olanzapine pamoate
JP5222917B2 (ja) * 2010-09-21 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法
EP2629775A4 (en) 2010-10-18 2014-06-11 Dainippon Sumitomo Pharma Co INJECTABLE FORMULATION WITH DELAYED RELEASE
JP6138703B2 (ja) 2011-03-18 2017-05-31 アルカームス ファーマ アイルランド リミテッド ソルビタンエステルを含む薬学的組成物
WO2013078608A1 (en) * 2011-11-29 2013-06-06 Ziqiang Gu Donepezil pamoate and methods of making and using the same
WO2013088255A1 (en) * 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
AU2013235523B9 (en) 2012-03-19 2018-01-04 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
AU2013235519C1 (en) 2012-03-19 2018-04-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
WO2013142205A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
US9193685B2 (en) 2012-09-19 2015-11-24 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
JP6042153B2 (ja) * 2012-09-26 2016-12-14 株式会社トクヤマ オランザピンの製造方法
EP3031449A4 (en) 2013-08-06 2017-05-10 Dong Kook Pharm. Co., Ltd Entecavir microspheres and pharmaceutical composition for parenteral administration containing same
WO2015079424A1 (en) 2013-11-29 2015-06-04 Simon Paul Mcdonald Dental wedge
JP6524110B2 (ja) 2014-03-20 2019-06-05 アルカームス ファーマ アイルランド リミテッド 注射速度が増大したアリピプラゾール調合物
ITUB20153652A1 (it) * 2015-09-16 2017-03-16 Fatro Spa Microsfere contenenti lattoni macrociclici antielminitici
WO2017053346A1 (en) * 2015-09-21 2017-03-30 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
JP2020511483A (ja) 2017-03-20 2020-04-16 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 徐放性オランザピン製剤
WO2019136308A1 (en) 2018-01-05 2019-07-11 Impel Neuropharma, Inc. Intranasal delivery of olanzapine by precision olfactory device
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN108969478A (zh) * 2018-08-29 2018-12-11 江南大学 一种美金刚难溶盐缓释注射剂及其制备方法
AU2021269223A1 (en) * 2020-05-05 2022-12-08 Syneurx International (Taiwan) Corp. Salts of neuroceuticals and uses thereof
CN112569191A (zh) * 2020-10-16 2021-03-30 长春斯菲尔生物科技有限公司 一种奥氮平双羟萘酸盐缓释微粒制剂喷雾制备方法
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
JP2025503013A (ja) * 2022-01-20 2025-01-30 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー オランザピン、その組成物及びその使用方法
WO2024107925A1 (en) * 2022-11-16 2024-05-23 Foresee Pharmaceuticals Co., Ltd. Depot compositions for vesicular monoamine transporter 2 (vmat2) inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3324192A1 (de) * 1983-07-05 1985-01-17 Troponwerke Gmbh & Co Kg Depot-antiphlogistika
US4816247A (en) * 1985-09-11 1989-03-28 American Cyanamid Company Emulsion compositions for administration of sparingly water soluble ionizable hydrophobic drugs
US4784845A (en) * 1985-09-16 1988-11-15 American Cyanamid Company Emulsion compostions for the parenteral administration of sparingly water soluble ionizable hydrophobic drugs
JPH01284333A (ja) * 1988-05-11 1989-11-15 T Hasegawa Co Ltd 乳化液組成物
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
CA2178592C (en) 1993-12-09 2009-07-28 Jurgen Engel Long-acting injection suspensions and a process for their preparation
JP3701693B2 (ja) * 1993-12-28 2005-10-05 日本製薬株式会社 鎮痛薬含有注射用徐放性脂肪乳剤
US6333021B1 (en) * 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
US5776928A (en) * 1995-04-21 1998-07-07 Eli Lilly And Company Method for treating dyskinesias with olanzapine
PT831835E (pt) * 1995-06-01 2003-01-31 Lilly Co Eli Metodo para tratamento da anorexia
US5602897A (en) * 1995-06-29 1997-02-11 Picker International, Inc. High-voltage power supply for x-ray tubes
US5891461A (en) 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
JPH09157159A (ja) * 1995-12-11 1997-06-17 Lion Corp カロチノイド含有組成物

Also Published As

Publication number Publication date
BR9813228A (pt) 2000-08-29
CA2304568C (en) 2008-08-12
CN1271251A (zh) 2000-10-25
WO1999016313A1 (en) 1999-04-08
AU752552B2 (en) 2002-09-19
JP2010138208A (ja) 2010-06-24
NZ503641A (en) 2002-09-27
TR200000812T2 (tr) 2001-07-23
US6169084B1 (en) 2001-01-02
HUP0004534A2 (hu) 2001-05-28
UA73715C2 (en) 2005-09-15
HUP0004534A3 (en) 2002-10-28
KR100537713B1 (ko) 2005-12-20
IL135295A0 (en) 2001-05-20
CA2304568A1 (en) 1999-04-08
NO20001631D0 (no) 2000-03-29
NO20001631L (no) 2000-05-30
PL339864A1 (en) 2001-01-15
CN1239158C (zh) 2006-02-01
EP1018880A4 (en) 2006-06-14
CZ300725B6 (cs) 2009-07-29
JP2001517685A (ja) 2001-10-09
CZ20001162A3 (cs) 2000-09-13
AU9591498A (en) 1999-04-23
ID25533A (id) 2000-10-12
HRP20000181A2 (en) 2000-12-31
JP4503826B2 (ja) 2010-07-14
EA002825B1 (ru) 2002-10-31
EP1018880A1 (en) 2000-07-19
EA200000381A1 (ru) 2000-10-30
IL135295A (en) 2006-10-31
KR20010030774A (ko) 2001-04-16
AU752552C (en) 2003-09-11

Similar Documents

Publication Publication Date Title
HRP20000181B1 (en) 2-methyl-thieno-benzodiazepine formulation
RS50485B (sr) Terapeutske kombinacije koje sadrže amplodipin i atorvastatin
DE69508837D1 (de) Protein enthaltende stabilisierte Formulierung und Dosierungskit
FI935638L (fi) Mobilassisterad handover som anvaender cdma
DZ1763A1 (fr) Composition vaccinantes.
FI922222A7 (fi) Kopplingsanordning, som foermaor laosa spinalosteosyntesfaestanordningar
FI925615L (fi) Stabiliserade farmaceutiska kompositioner, som innehaoller en HMG-CoA-reduktas-inhibitorfoerening
DK1719511T3 (da) N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methansulfonamid, en farmaceutisk sammensætning omfattende samme, og anvendelse deraf
FI943465A7 (fi) Hengittävä mäntä käyttöinjektiolaitteita varten
DZ1835A1 (fr) Nouvelles formulations.
FR2701538B3 (fr) Gyrophare.
FI923281L (fi) Foerbaettrade desinfektionsloesningar, som innehaoller vaeteperoxid
NO911949D0 (no) Tgf-beta-preparater.
HRP20010238B1 (en) 2-methyl-thieno-benzodiazepine formulation
FI922973A0 (fi) Tokoferolblandning foer anvaendning som antioxidant foer krusmyntolja i tuggummi.
FI920271L (fi) Polyamintioler som straolningsskyddande aemnen.
DE69014274D1 (de) Kolbenkühlungsdüse.
DE69110468D1 (de) Hochdrucksprühkopf.
FI920435A7 (fi) N-(aryloxyalkyl) heteroaryl-8 -azabicyclo/3.2.1./oktaner, mellanprodukter och deras framstaellnings -foerfarande och deras anvaendning som laekemedel.
FI920192L (fi) Substituerade 1,2,3,4-tetrahydro -cyklopent/b/indoler, 1,2,3,3a,4,8a-hexahydrocyklopent/b/indoler och motsvarande foereningar, mellanprodukter och foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
FI933719L (fi) 4-((2-bensotiazolyl)metylamino)-a-((3,4-difluorfenoxi)metyl)-1-piperidinetanol
YU48915B (sh) Sulfonilkarbamid i postupak za njegovo dobijanje
DE69430362D1 (de) Ektoparasitizide formulierung
FI925875L (fi) Foerfarande foer framstaellning av nya som inhibitorer av proteolytiska enzymer anvaendbara 2-sackarinylmetyl- och 4,5,6,7-tetrahydro-2-sackarinylmetylfosfater, -fosfonater och -fosfinater
FI913005L (fi) Verkande aemnen som bundits pao ett frigoerbart saett.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20110916

Year of fee payment: 14

PBON Lapse due to non-payment of renewal fee

Effective date: 20121001